Needham Maintains Buy on Trevi Therapeutics, Raises Price Target to $24

Benzinga Newsdesk www.benzinga.com Positive 76.7%

Neg 0% Neu 0% Pos 76.7%

Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $22 to $24.